TY - JOUR
T1 - Bone disease in monoclonal gammopathy of undetermined significance
T2 - Results from a screened population-based study
AU - Thorsteinsdottir, Sigrun
AU - Lund, Sigrun H.
AU - Lindqvist, Ebba K.
AU - Thordardottir, Marianna
AU - Sigurdsson, Gunnar
AU - Costello, Rene
AU - Burton, Debra
AU - Steingrimsdottir, Hlif
AU - Gudnason, Vilmundur
AU - Eiriksdottir, Gudny
AU - Siggeirsdottir, Kristin
AU - Harris, Tamara B.
AU - Landgren, Ola
AU - Kristinsson, Sigurdur Y.
N1 - Funding Information:
This work was supported by grants from the University of Iceland Research Fund, Icelandic Centre for Research (RANNIS), Landspitali University Hospital Research Fund, Karolinska Institutet Foundations, and Marie Curie Career Integration Grants (CIG). Furthermore, this work was funded by National Institutes of Health, National Institute on Aging (NIA) contractN01-AG012100, theNIA Intramural Research Program, an Intramural Research Program Award (ZIAEY000401) from the National Eye Institute, an award from the National Institute on Deafness and Other Communication Disorders Division of Scientific Programs (IAA Y2-DC_1004-02), Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). This work was also supported by National Cancer Institute Memorial Sloan Kettering Cancer Center core grant (P30 CA008748). The work was approved by the Icelandic National Bioethics Committee (VSN 00-063).
Funding Information:
This work was supported by grants from the University of Iceland Research Fund, Icelandic Centre for Research (RANNIS), Land-spitali University Hospital Research Fund, Karolinska Institutet
Funding Information:
Foundations, and Marie Curie Career Integration Grants (CIG). Furthermore, this work was funded by National Institutes of Health, National Institute on Aging (NIA) contract N01-AG012100, the NIA Intramural Research Program, an Intramural Research Program Award (ZIAEY000401) from the National Eye Institute, an award from the National Institute on Deafness and Other Communication Disorders Division of Scientific Programs (IAA Y2-DC_1004-02), Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). This work was also supported by National Cancer Institute Memorial Sloan Kettering Cancer Center core grant (P30 CA008748). The work was approved by the Icelandic National Bioethics Committee (VSN 00-063).
Publisher Copyright:
© 2017 American Society of Hematology. All rights reserved.
PY - 2017/12/26
Y1 - 2017/12/26
N2 - Previous studies have shown that individuals with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of fractures, although the underlying mechanisms remain unknown. Our aim was to analyze bone mineral density (BMD), bone volume, and risk of fractures among individuals with MGUS. We performed a screening using the Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study cohort, consisting of 5764 elderly individuals, identifying 300 individuals with MGUS, and 275 with light-chain MGUS. Quantitative computerized tomography was performed in the lumbar spine and hip to evaluate BMD and bone geometry. Analysis of variance and the Tukey honest significance test were used to compare the groups. Hospital records were used to record fractures, with a mean follow-up of 6.9 years. Cox proportional hazard was used to compare fracture risk. No difference was found in BMD between subjects with MGUS and others in the spine (P = .34) or in total hip (P = .30). Individuals with MGUS had a significant increase in bone volume compared with others in the spine (P < .001) and total hip (P < .001). Overall, the risk of fractureswas not significantly increased in individualswithMGUS (hazard ratio [HR], 1.19; 95% confidence interval [CI], 0.94-1.50). Men with MGUS had a significantly increased fracture risk, compared with other men (HR, 1.46; 95% CI, 1.03-2.08). Our results show that although individuals with MGUS do not have decreased BMD, bone volume is increased, and MGUS men have a 50% increased fracture risk. These results indicate that bone disease and fractures in MGUS differ from processes known from osteoporosis.
AB - Previous studies have shown that individuals with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of fractures, although the underlying mechanisms remain unknown. Our aim was to analyze bone mineral density (BMD), bone volume, and risk of fractures among individuals with MGUS. We performed a screening using the Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study cohort, consisting of 5764 elderly individuals, identifying 300 individuals with MGUS, and 275 with light-chain MGUS. Quantitative computerized tomography was performed in the lumbar spine and hip to evaluate BMD and bone geometry. Analysis of variance and the Tukey honest significance test were used to compare the groups. Hospital records were used to record fractures, with a mean follow-up of 6.9 years. Cox proportional hazard was used to compare fracture risk. No difference was found in BMD between subjects with MGUS and others in the spine (P = .34) or in total hip (P = .30). Individuals with MGUS had a significant increase in bone volume compared with others in the spine (P < .001) and total hip (P < .001). Overall, the risk of fractureswas not significantly increased in individualswithMGUS (hazard ratio [HR], 1.19; 95% confidence interval [CI], 0.94-1.50). Men with MGUS had a significantly increased fracture risk, compared with other men (HR, 1.46; 95% CI, 1.03-2.08). Our results show that although individuals with MGUS do not have decreased BMD, bone volume is increased, and MGUS men have a 50% increased fracture risk. These results indicate that bone disease and fractures in MGUS differ from processes known from osteoporosis.
UR - http://www.scopus.com/inward/record.url?scp=85053518121&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053518121&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2017010454
DO - 10.1182/bloodadvances.2017010454
M3 - Article
AN - SCOPUS:85053518121
VL - 1
SP - 2790
EP - 2798
JO - Blood advances
JF - Blood advances
SN - 2473-9529
IS - 27
ER -